• 1
    Kanda T, Raychoudhuri A, Steele R, et al. MBP-1 inhibits breast cancer growth and metastasis in immunocompetent mice. Cancer Res 2009;69:93549.
  • 2
    Coughlin SS, Ekwueme DU. Breast cancer as a global health concern. Cancer Epidemiol 2009;33:3158.
  • 3
    Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:1130.
  • 4
    Chen WQ, Zheng RS, Zhang SW, et al. Report of incidence and mortality in china cancer registries, 2008. Chin J Cancer Res 2012;24:17180.
  • 5
    Liu F, Lang R, Zhao J, et al. CD8+ cytotoxic T cell and FOXP3+ regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes. Breast Cancer Res Treat 2011;130:64555.
  • 6
    DeNardo DG, Brennan DJ, Rexhepaj E, et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov 2011;1:5467.
  • 7
    Khoury T, Sait S, Hwang H, et al. Delay to formalin fixation effect on breast biomarkers. Mod Pathol 2009;22:145767.
  • 8
    Trerotola M, Jernigan DL, Liu Q, et al. Trop-2 promotes prostate cancer metastasis by modulating β(1) integrin functions. Cancer Res 2013;73:315567.
  • 9
    Ohmachi T, Tanaka F, Mimori K, et al. Clinical significance of TROP2 expression in colorectal cancer. Clin Cancer Res 2006;12:305763.
  • 10
    Cubas R, Li M, Chen C, et al. Trop2: A possible therapeutic target for late stage epithelial carcinomas. Biochim Biophys Acta 2009;1796:30914.
  • 11
    Ripani E, Sacchetti A, Corda D, et al. Human Trop-2 is a tumor-associated calcium signal transducer. Int J Cancer 1998;76:6716.
  • 12
    Sukhthankar M, Alberti S, Baek SJ. (-)-Epigallocatechin-3-gallate (EGCG) post-transcriptionally and post-translationally suppresses the cell proliferative protein TROP2 in human colorectal cancer cells. Anticancer Res 2010;30:2497503.
  • 13
    Fong D, Spizzo G, Gostner JM, et al. TROP2: a novel prognostic marker in squamous cell carcinoma of the oral cavity. Mod Pathol 2008;21:18691.
  • 14
    Nakashima K, Shimada H, Ochiai T, et al. Serological identification of TROP2 by recombinant cDNA expression cloning using sera of patients with esophageal squamous cell carcinoma. Int J Cancer 2004;112:102935.
  • 15
    Mühlmann G, Spizzo G, Gostner J, et al. TROP2 expression as prognostic marker for gastric carcinoma. J Clin Pathol 2009;62:1528.
  • 16
    Wang J, Day R, Dong Y, et al. Identification of Trop-2 as an oncogene and an attractive therapeutic target in colon cancers. Mol Cancer Ther 2008;7:2805.
  • 17
    Fong D, Moser P, Krammel C, et al. High expression of TROP2 correlates with poor prognosis in pancreatic cancer. Br J Cancer 2008;99:12905.
  • 18
    Bignotti E, Todeschini P, Calza S, et al. Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patients. Eur J Cancer 2010;46:94453.
  • 19
    Lin H, Huang JF, Qiu JR, et al. Significantly upregulated TACSTD2 and Cyclin D1 correlate with poor prognosis of invasive ductal breast cancer. Exp Mol Pathol 2013;94:738.
  • 20
    Jiao Y, Zhao P, Zhu J, et al. Construction of human naive Fab library and characterization of anti-met Fab fragment generated from the library. Mol Biotechnol 2005;31:4154.
  • 21
    Huang H, Groth J, Sossey-Alaoui K, et al. Aberrant expression of novel and previously described cell membrane markers in human breast cancer cell linesand tumors. Clin Cancer Res 2005;11:435764.
  • 22
    Wang J, Day R, Dong Y, et al. Identification of Trop-2 as an oncogene and an attractive therapeutic target in colon cancers. Mol Cancer Ther 2008;7:2805.
  • 23
    Chen R, Zhang D, Mao Y, et al. A human Fab-based immunoconjugate specific for the LMP1 extracellular domain inhibits nasopharyngeal carcinoma growth in vitro and in vivo. Mol Cancer Ther 2012,11:594603.
  • 24
    Lin H, Mao Y, Zhang DW, et al. Selection and Characterization of Human Anti-MAGE-A1 scFv and Immunotoxin. Anticancer Agents Med Chem 2013 [Epub ahead of print]
  • 25
    Lin HH, Li X, Chen JL, et al. Identification of an AAA ATPase VPS4B-dependent pathway that modulates epidermal growth factor receptor abundance and signaling during hypoxia. Mol Cell Biol 2012;32:112438.
  • 26
    Mao Y, Zhang DW, Wen J, et al. A novel LMP1 antibody synergizes with Mitomycin C to inhibit nasopharyngeal carcinoma growth in vivo through inducing apoptosis and downregulating vascular endothelial growth factor. Int J Mol Sci 2012;13:220818.
  • 27
    Mao Y, Zhang DW, Zhu H, et al. LMP1 and LMP2A are potential prognostic markers of extranodal NK/T-cell lymphoma, nasal type (ENKTL). Diagn Pathol 2012;7:178.
  • 28
    Mao Y, Zhang DW, Lin H, et al. Alpha B-crystallin is a new prognostic marker for laryngeal squamous cell carcinoma. J Exp Clin Cancer Res 2012;31:101.
  • 29
    Yardley DA, Hart L, Bosserman L, et al. Phase II study evaluating lapatinib in combination with nab-paclitaxel in HER2-overexpressing metastatic breast cancer patients who have received no more than one prior chemotherapeutic regimen. Breast Cancer Res Treat 2013;137:45764.
  • 30
    Jubb AM, Miller KD, Rugo HS, et al. Impact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast cancer. Clin Cancer Res 2011;17:37281.
  • 31
    Alberti S, Trerotola M, Vacca G, et al. TROP2 is a major determinant of growth and metastatic spreading of human cancer. J Clin Oncol 2007;25:10510.
  • 32
    Chang CH, Gupta P, Michel R, et al. Ranpirnase (frog RNase) targeted with a humanized, internalizing, anti-Trop-2 antibody has potent cytotoxicityagainst diverse epithelial cancer cells. Mol Cancer Ther 2010;9:227686.
  • 33
    Cardillo TM, Govindan SV, Sharkey RM, et al. Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys. Clin Cancer Res 2011;17:315769.
  • 34
    Sharkey RM, vanRij CM, Karacay H, et al. A new tri-Fab bispecfic antibody for pretargeting Trop-2-expressing epithelial cancers. J Nucl Med 2012;53:162532.
  • 35
    Cubas R, Zhang S, Li M, et al. Trop-2 expression contributes to tumor pathogenesis by activating the ERK MAPK pathway. Mol Cancer 2010;9:25365.
  • 36
    Bignotti E, Zanotti L, Calza S, et al. Trop-2 protein overexpression is an independent marker for predicting disease recurrence in endometrioid endometrial carcinoma. BMC Clin Pathol 2012;12:22.
  • 37
    Huang Q, Li F, Liu X, et al. Caspase 3-mediated stimulation of tumor cell repopulation during cancer radiotherapy. Nat Med 2011;17:8606.
  • 38
    Faião-Flores F, Coelho PR, Toledo Arruda-Neto JD, et al. Apoptosis through Bcl-2/Bax and cleaved caspase up-regulation in melanoma treated by boron neutron capture therapy. PLoS One 2013;8:e59639.
  • 39
    Rajah TT, Peine KJ, Du N, et al. Physiological concentrations of genistein and 17β-estradiol inhibit MDA-MB-231 breast cancer cell growth by increasing BAX/BCL-2 and reducing pERK1/2. Anticancer Res 2012;32:118191.
  • 40
    Boucher M, Morisset J, Vachon PH, et al. MEK/ERK signaling pathway regulates the expression of Bcl-2, Bcl-Xl, and Mcl-1 and promotes survival of human pancreatic cancer cells. J Cell Biochem 2000;79:35569.